Slide 1: Earnings Call Q1 2026
˥ May 20 , 2026 EARNINGS CALL Q 1 2026 OFER HAVIV | PRESIDENT & CEO
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation contains "forward - looking statements" relating to future events, and Evogene Ltd. ( the “ Company ” ) , may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters rega
Slide 3: Agenda
˧ EARNINGS CALL Q 1 2026 AGENDA - By Ofer Haviv CEO UPDATE - By Polina Ravzin VP FINANCE UPDATE Q&A
Slide 4: Evogene Pioneers Real-World Innovation
EVOGENE PIONEERS REAL - WORLD INNOVATION Using a proprietary generative AI engine, we design highly potent and novel small molecules, optimized across multiple - parameters, for the pharmaceutical and ag - chemical industries 4
Slide 5: Pharma and Ag Divisions External Collaborations
5 PHARMA DIVISION – DRUGS EXTERNAL COLLABORATIONS Metabolic Disease EXTERNAL COLLABORATIONS Herbicides Herbicides INTERNAL PIPELINE Wheat Blotch Evogene – End Of 2025 AG DIVISION* – AG - CHEMICALS AG DIVISION ͐ – Operations in this field are conducted through our subsidiary, AgPlenus . First collabo
Slide 6: Evogene Core Technology ChemPass AI
6 PHARMA DIVISION – DRUGS Evogene C ore Technology ChemPass AI - As Of Today ( 19.05.2026 ) AG DIVISION* – AG - CHEMICALS AG DIVISION ͐ – Operations in this field are conducted through our subsidiary, AgPlenus . Second collaboration advanced AI agents integration
Slide 7: Technological Collaborations with Google Cloud
7 TECHNOLOGICAL COLLABORATIONS WITH GOOGLE CLOUD FROM GENERATIVE MODELS TO AUTONOMOUS DISCOVERY FIRST COLLABORATION – FIRST - IN - CLASS FOUNDATION MODEL Successful completion of a proprietary generative AI model for novel molecular product candidates addressing multiple parameters, based on 38 bill
Slide 8: Pharma Division External Collaborations
8 PHARMA DIVISION – DRUGS EXTERNAL COLLABORATIONS Metabolic Disease AG DIVISION* – AG - CHEMICALS AG DIVISION ͐ – Operations in this field are conducted through our subsidiary, AgPlenus . Neutrophil - Derived Inflammatory Diseases Demyelination Disorders Lung Cancer Second collaboration advancd AI a
Slide 9: Collaboration with Systasy Biosciences and LMU Munich
PHARMA DIVISION 9 • Target : novel mechanism addressing large unmet needs in hyperinflammatory diseases such as inflammatory bowel disease (IBD) . • Addressable IBD market : valued at USD 20 billion in 2024 , with projections approximately USD 33 billion by 2032 * . • Combines ChemPass AI , Systasy
Slide 10: Collaboration with Unravel Biosciences
COLLABORATION WITH UNRAVEL BIOSCIENCES, BOSTON, USA NOVEL THERAPIES FOR DEMYELINATION DISORDERS PHARMA DIVISION 10 Molecular modelling of putative modulator (green) in its target (surface in grey and interacting protein residues in colored spheres) “ We are thrilled to partner with Evogene to desi
Slide 11: Collaboration with Dr. Mark Adams, QUT
COLLABORATION WITH DR. MARK ADAMS, QUT, BRISBANE, AUSTRALIA NOVEL THERAPIES FOR CHEMOTHERAPY RESISTANCE IN CANCER TREATMENT PHARMA DIVISION 11 Different ligands interact with distinct residues and occupy the pocket with diverse orientations “ Partnering with Evogene is an exciting opportunity not on
Slide 12: Diversified Small Molecule Pipeline
12 DIVERSIFIED SMALL MOLECULE PIPELINE ( 19.05.2026 ) PARTNER IND PRE - CLINICAL LEAD OPTIMIZATION HIT - TO - LEAD HIT ID INDICATION PROGRAM Immunology EVGI 110 Neurology EVGN 210 Oncology EVGO 310 Metabolism* EVGM 410 * Non - protein target
Slide 13: Evogene As of Today
13 PHARMA DIVISION – DRUGS EXTERNAL COLLABORATIONS Metabolic Disease EXTERNAL COLLABORATIONS Herbicides INTERNAL PIPELINE Wheat Blotch AG DIVISION* – AG - CHEMICALS AG DIVISION ͐ – Operations in this field are conducted through our subsidiary, AgPlenus . Neutrophil - Derived Inflammatory Diseases De
Slide 14: Internal Pipeline: Wheat Blotch
INTERNAL PIPELINE WHEAT BLOTCH 14 1 ) TResearch Summer 2019 2 ) Global Growth Insights DISRUPTING A $ 1.2 B PROBLEM AT RECORD SPEED • 70 % of EU fungicide usage in wheat is for Wheat Blotch 1 • EU market alone >$ 1.2 B annually 1 • Widespread resistance to current top products ( ‘ Strobilurins ’ ) w
Slide 15: End-to-End Process for Optimized Molecules
END - TO - END PROCESS – NOVEL, HIGHLY POTENT, OPTIMIZED MOLECULES WHEAT BLOTCH, DISRUPTING A $ 1.2 B PROBLEM AT RECORD SPEED* • 70 % of EU fungicides are used for Wheat Blotch • Widespread resistance to current products HIT SCREENING WITH POINTHIT TM LEAD OPTIMIZATION WITH LEADOP GPT TM Step 1 Step
Slide 16: Diversified Small Molecule Pipeline
16 DIVERSIFIED SMALL MOLECULE PIPELINE ( 19.05.2026 ) PARTNER IND PRE - CLINICAL LEAD OPTIMIZATION HIT - TO - LEAD HIT ID INDICATION PROGRAM Immunology EVGI 110 Neurology EVGN 210 Oncology EVGO 310 Metabolism* EVGM 410 PARTNER FIELD TESTING SAFETY & ENVIRONMENT LEAD OPTIMIZATION HIT - TO - LEAD HIT
Slide 17: Evogene Looking Forward
17 PHARMA DIVISION – DRUGS EVOGENE – LOOKING FORWARD AG DIVISION* – AG - CHEMICALS AG DIVISION ͐ – Operations in this field are conducted through our subsidiary, AgPlenus . Additional tech collaborations to maintain our competitive advantage • Progress in existing pipeline ͅ • New collaborations wit
Slide 18: Agenda
˥ˬ EARNINGS CALL Q 1 2026 AGENDA - By Ofer Haviv CEO UPDATE - By Polina Ravzin VP FINANCE UPDATE Q&A unique
Slide 19: Evogene Subsidiaries' Activity
˥˭ 19 EVOGENE SUBSIDIARIES ’ ACTIVITY
Slide 20: Evogene Subsidiaries' Activity
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC 128 , a Microbiome - Based Therapeutic for Renal and Lung Cancer Evogene Announces Completion of Transaction for the Sale of Lavie Bio ’ s Activity to ICL 20 EVOGENE SUBSIDIARIES ’ ACTIVITY
Slide 21: Evogene Subsidiaries' Activity
˦˥ 21 EVOGENE SUBSIDIARIES ’ ACTIVITY
Slide 22: Evogene Subsidiaries' Activity: Casterra
22 EVOGENE SUBSIDIARIES ’ ACTIVITY • Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock . • Casterra completed the 2026 planting of 13 trials across 7 Brazilian states : Bahia, Ceara, Goias, Maran
Slide 23: VP Finance Update Financial Highlights
˦˧ VP FINANCE UPDATE FINANCIAL HIGHLIGHTS
Slide 24: VP Finance Update Financial Highlights
˦˨ VP FINANCE UPDATE FINANCIAL HIGHLIGHTS
Slide 25: VP Finance Update Financial Highlights
˦˩ VP FINANCE UPDATE FINANCIAL HIGHLIGHTS
Slide 26: Agenda
˦˪ EARNINGS CALL Q 1 2026 AGENDA - By Ofer Haviv CEO UPDATE - By Polina Ravzin VP FINANCE UPDATE Q&A
Slide 27: Creating Real-World Innovation for a Better Future
Creating REAL-WORLD INNOVATION for a better future evOgene *